{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06287463",
            "orgStudyIdInfo": {
                "id": "DCC-3084-01-001"
            },
            "organization": {
                "fullName": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway",
            "officialTitle": "A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-dcc-in-participants-with-advanced-malignancies-driven-by-the-mitogen-activated-protein-kinase-mapk-pathway"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-23",
            "studyFirstSubmitQcDate": "2024-02-23",
            "studyFirstPostDateStruct": {
                "date": "2024-03-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "RAF Mutation",
                "RAS Mutation",
                "NF1 Mutation",
                "Non-Small Cell Lung Cancer",
                "Pancreatic Ductal Adenocarcinoma",
                "Melanoma",
                "BRAF Gene Mutation",
                "CRAF Gene Mutation"
            ],
            "keywords": [
                "Advanced malignancies"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DCC-3084 Module A Escalation Phase (ModA Part 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive DCC-3084 in ModA Part 1, Escalation Phase.",
                    "interventionNames": [
                        "Drug: DCC-3084"
                    ]
                },
                {
                    "label": "DCC-3084 Module A Expansion Phase (ModA Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive DCC-3084 in ModA Part 2, Expansion Phase.",
                    "interventionNames": [
                        "Drug: DCC-3084"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DCC-3084",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "DCC-3084 Module A Escalation Phase (ModA Part 1)",
                        "DCC-3084 Module A Expansion Phase (ModA Part 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1)",
                    "description": "DLTs reported during ModA Part 1.",
                    "timeFrame": "Cycle 1 (28 days)"
                },
                {
                    "measure": "Objective Response Rate (ORR) (ModA Part 2)",
                    "description": "ORR is the percentage of participants with confirmed complete or partial remission based on indication specific criteria as defined in the protocol.",
                    "timeFrame": "Start of Therapy to Progressive Disease (PD), Death Due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "ORR (ModA Part 1)",
                    "description": "ORR is the percentage of participants with confirmed complete or partial remission based on indication specific criteria as defined in the protocol.",
                    "timeFrame": "Start of Therapy to PD, Death Due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)"
                },
                {
                    "measure": "Progression-Free Survival (PFS) (ModA Part 1 and 2)",
                    "description": "PFS is the time from start of therapy to PD or death due to any cause.",
                    "timeFrame": "Start of Therapy to PD or Death Due to Any Cause (Estimated up to 24 months)"
                },
                {
                    "measure": "Overall Survival (OS) (ModA Part 1 and 2)",
                    "description": "OS is the time from start of therapy to death from any cause.",
                    "timeFrame": "Start of Therapy to Death Due to Any Cause (Estimated up to 36 months)"
                },
                {
                    "measure": "Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) (ModA Part 1 and 2)",
                    "description": "Cmax (ModA Part 1 and 2)",
                    "timeFrame": "Predose up to 12 hours postdose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nGeneral Inclusion Criteria ModA Part 1 and 2:\n\n* Able to provide a fresh tumor biopsy from a primary or metastatic cancer lesion and an archival tumor tissue sample, if available\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening\n* Has a life expectancy of more than 6 months\n* In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria\n\nInclusion Criteria ModA Part 1 Cohort Specific:\n\n* Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation\n* Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator\n\nInclusion Criteria ModA Part 2 Cohort Specific:\n\n* Documented BRAF gene mutation\n* Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria ModA Part 1 and 2:\n\n* Prior treatment with certain BRAF dimer inhibitors\n* Female participant is pregnant or lactating\n* Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days\n* Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084\n* Known allergy or hypersensitivity to any component of the study drug\n* Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* Impaired cardiac function\n* History of recent thrombotic or embolic events\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Major surgery within 28 days of the first dose of study drug\n* In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria\n\nExclusion Criteria: Module A Part 2 Cohort Specific:\n\n\u2022 Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Team",
                    "role": "CONTACT",
                    "phone": "785-830-2100",
                    "email": "clinicaltrials@deciphera.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Southern California - Norris Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony El-Khoueiry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "SCRI HealthONE",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gerald Falchook, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "SCRI Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32827",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cesar Perez Batista, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vivek Subbiah, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ildefonso Ismael Rodriguez Rivera, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "NEXT Oncology Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M19549",
                    "name": "Neurofibromatoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M12399",
                    "name": "Neurofibromatosis 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4096",
                    "name": "Neurofibromatosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4097",
                    "name": "Neurofibromatosis Type 1",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}